Mab-B3

N/A

Report date: 2022/01/14 13:23:58

Base Information

Drug NameMab-B3
Drug Alias NameMab-B3
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Chimeric monoclonal antibody
Mechanisms of ActionDickkopf-related protein 1 inhibitors
TargetsDickkopf-related protein 1
Therapy Area/IndicationsBone Diseases
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryN/A
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesEli Lilly And Company
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesEli Lilly And Company
Active IndicationsN/A
Inactive IndicationsBone Diseases

Other Information

ATC CodeN/A
Related LinksN/A